Repligen Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGEN research report →
About the company
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing.
- CEO
- Olivier Loeillot
- IPO
- 1986
- Employees
- 2,000
- HQ
- Waltham, MA, US
Price Chart
Get TickerSpark's AI analysis on RGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $8.31B
- P/E
- 161.81
- P/S
- 10.88
- P/B
- 3.94
- EV/EBITDA
- 48.74
- Div Yield
- 0.00%
- Gross Margin
- 50.25%
- Op Margin
- 8.81%
- Net Margin
- 6.73%
- ROE
- 2.46%
- ROIC
- 2.18%
- Revenue
- $738.26M · 16.36%
- Net Income
- $48.89M · 291.64%
- EPS
- $0.87 · 289.13%
- Op Income
- $59.58M
- FCF YoY
- -34.10%
- 52W High
- $175.77
- 52W Low
- $100.99
- 50D MA
- $128.41
- 200D MA
- $140.10
- Beta
- 1.06
- Avg Volume
- 1.14M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 16, 26 | Garland Jason K | sell | 530 |
| Jun 25, 26 | Garland Jason K | sell | 733 |
| May 14, 26 | Madaus Martin D | other | 995 |
| May 14, 26 | Madaus Martin D | other | 2,239 |
| May 14, 26 | Konstantinov Konstantin | other | 995 |
| May 14, 26 | Konstantinov Konstantin | other | 2,239 |
| May 14, 26 | EGLINTON MANNER CARRIE | other | 995 |
| May 14, 26 | Mhatre Rohin | other | 995 |
| May 14, 26 | Mhatre Rohin | other | 2,239 |
| May 14, 26 | EGLINTON MANNER CARRIE | other | 2,239 |
Our RGEN coverage
Recent articles, reports, and earnings notes.
Intuitive Surgical’s selloff looks overdone if Da Vinci 5 is the real story
Intuitive Surgical just got hit like the growth story broke, yet the quarter said the opposite. Revenue rose 19%, procedures stayed double-digit, and da Vinci 5 placements kept climbing, which makes this look more like an expectations reset than a business problem.
Intuitive Surgical is expensive for a reason
Intuitive Surgical trades at a premium because it is still delivering premium operating results. With procedure growth running around 17%, revenue up 20.5%, and the da Vinci installed base still expanding double digits, the usual "too expensive" knock misses what the business is actually doing.
Want a deeper read on RGEN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.